更正：曼库索等人。奋勇前行：来那度胺难治性多发性骨髓瘤的二线治疗选择。2025年，，1168。 （你提供的原文中部分内容似乎不完整，比如中间有两个逗号隔开但无具体内容，以上是按照完整能理解的部分翻译的）
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. 2025, , 1168.
作者信息
Mancuso Katia, Barbato Simona, Raimondo Francesco Di, Gay Francesca, Musto Pellegrino, Offidani Massimo, Petrucci Maria Teresa, Zamagni Elena, Zambello Renato, Cavo Michele
机构信息
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy.
Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, 40138 Bologna, Italy.
出版信息
Cancers (Basel). 2025 Aug 1;17(15):2555. doi: 10.3390/cancers17152555.
Abstract
The authors have separated the affiliations originally listed in affiliation 4-this is so both affiliations can be organized from subordinate to superior [...].
摘要
作者们对最初列在机构4中的附属机构进行了拆分——这样做是为了使两个附属机构都能从下级到上级进行组织安排[……]。
相似文献
1
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. 2025, , 1168.更正：曼库索等人。奋勇前行：来那度胺难治性多发性骨髓瘤的二线治疗选择。2025年，，1168。 （你提供的原文中部分内容似乎不完整，比如中间有两个逗号隔开但无具体内容，以上是按照完整能理解的部分翻译的）
Cancers (Basel). 2025 Aug 1;17(15):2555. doi: 10.3390/cancers17152555.
3
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.奋勇前行：来那度胺难治性多发性骨髓瘤的二线治疗选择
Cancers (Basel). 2025 Mar 30;17(7):1168. doi: 10.3390/cancers17071168.
4
The Role of CELMoD Agents in Multiple Myeloma.CELMoD药物在多发性骨髓瘤中的作用。
Onco Targets Ther. 2025 Aug 27;18:921-933. doi: 10.2147/OTT.S398118. eCollection 2025.
5
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.卡非佐米-来那度胺-地塞米松对比来那度胺-地塞米松治疗不适合自体干细胞移植的新诊断骨髓瘤患者（EMN20）：一项随机、开放标签、多中心3期试验
Lancet Haematol. 2025 Aug;12(8):e621-e634. doi: 10.1016/S2352-3026(25)00162-0.
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
8
Pharmacoeconomic evaluation of carfilzomib ixazomib for the treatment of relapsed and refractory multiple myeloma.卡非佐米与伊沙佐米治疗复发难治性多发性骨髓瘤的药物经济学评价
Future Sci OA. 2025 Dec;11(1):2514969. doi: 10.1080/20565623.2025.2514969. Epub 2025 Jun 18.
9
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
10
Severe Relapsing Hailey-Hailey Disease Displaying a Durable Complete Response to Hydroxyurea.严重复发性黑利-黑利病对羟基脲呈现持久完全缓解
Acta Dermatovenerol Croat. 2024 Nov;32(3):168-169.
本文引用的文献
1
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.奋勇前行：来那度胺难治性多发性骨髓瘤的二线治疗选择
Cancers (Basel). 2025 Mar 30;17(7):1168. doi: 10.3390/cancers17071168.
Zotero 插件